Michael Rogawski

Dr. Michael Rogawski is a professor at the University of California-Davis in the Department of Neurology, with a joint appointment in the Department of Pharmacology, and an affiliate member of the Center for Neuroscience. Until 2006, he was a senior investigator and chief of the Epilepsy Research Section at the National Institute of Neurological Disorders and Stroke (NINDS). Dr. Rogawski received his BA from Amherst College and MD and Ph.D. (pharmacology) degrees from Yale University. After serving as a postdoctoral fellow in the Laboratory of Neurophysiology at NINDS, he completed residency training in neurology at Johns Hopkins. Dr. Rogawski was chair of the UC Davis Department of Neurology until 2012. His research encompasses animal models of epilepsy, migraine, and nerve agent intoxication, as well as clinical studies on new treatments for seizures, epilepsy, migraine, traumatic brain injury, and neurodevelopmental disorders. His laboratory studies on AMPA receptors and neurosteroids have led to new treatment approaches for seizures and epilepsy and the marketed treatment for postpartum depression, brexanolone (Zulresso™). Dr. Rogawski has served on the editorial boards of the journals Molecular Pharmacology, Epilepsia, Epilepsy Research, Synapse, CNS Drug Reviews, Current Neuropharmacology, Pharmacology & Therapeutics, BMC Pharmacology, Cellular, and Molecular Neurobiology, and Nature Scientific Reports, and was executive editor of Neuropharmacology and associate editor of Neurotherapeutics.